Evidence map›Paper›PMID 40303929›Full record

ArticleFrontiers in pharmacology2025

Construction and application of a precise evaluation method for the quality of traditional Chinese medicine based on "target-combined quality evaluation" using safflower as an example.

Yongfeng Zhou, Qinghua Wu, Chaoxiang Ren, Huajuan Jiang, Xulong Huang, Jiang Chen, Ping Zhang, Dingkun Zhang, Jin Pei

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yongfeng Zhou *Department of Pharmacy, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China.
Qinghua Wu *State Key Laboratory of Southwestern Chinese Medicine Resources, College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Chaoxiang RenState Key Laboratory of Southwestern Chinese Medicine Resources, College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Huajuan JiangState Key Laboratory of Southwestern Chinese Medicine Resources, College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Xulong HuangState Key Laboratory of Southwestern Chinese Medicine Resources, College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Jiang ChenState Key Laboratory of Southwestern Chinese Medicine Resources, College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Ping ZhangMedical Supplies Center of PLA General Hospital, Beijing, China.
Dingkun ZhangState Key Laboratory of Southwestern Chinese Medicine Resources, College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Jin PeiState Key Laboratory of Southwestern Chinese Medicine Resources, College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The quality of traditional Chinese medicine (TCM) guarantees clinical efficacy. At present, although chemical quality evaluation methods can reflect the quality of TCMs to a certain extent, there are still many problems. This study proposes a new strategy for the quality innovation evaluation of the TCM "target combined quality evaluation" (TCQE) theory and method. Taking the "disease-target-medicine" combination as the main fusion strategy, using drug components/ components to achieve the overall intervention of disease targets, and establishing the TCQE strategy of TCM to improve the pertinence and accuracy of the quality evaluation of TCM, the clinical efficacy and safety of TCM is improved, and precision clinical medication is achieved. Methods: Taking safflower as the research object, due to its main efficacy in the treatment of primary dysmenorrhea (PD), the potential targets and mechanism of action of safflower in the treatment of PD were analyzed by a network pharmacology method and combined with a metabolomics method. The pathway and mechanism of action of safflower in the treatment of PD were analyzed from multiple dimensions. The network pharmacology and metabolomics results were analyzed, the key targets of safflower in the treatment of PD were screened. Finally, a method for the biological evaluation of safflower quality was established based on the selected targets, which could provide a reference for the precise evaluation of safflower treatment and a scientific basis for the clinical application of safflower in the prevention and treatment of PD. Results and discussion: The pharmacodynamic results showed that Safflower significantly improved Prostaglandin E2 (PGE2) and Prostaglandin F2 α (PGF2 α) levels, the PGF2 α/PGE2 ratio and the analgesic rate in PD rats. The results of network pharmacology combined with metabolomics analysis showed that Prostaglandin G/H synthase 2 (PTGS2) and arachidonic acid (AA)were important targets and pathways of Safflower in the treatment of PD. A biological evaluation method was established around PTGS2. The results of the methodological investigation showed that the method was stable and reliable. In vivo validation experiments showed that the results of this method were consistent with the pharmacodynamic results, which proved its accuracy. PTGS2 is an important target of safflower in the treatment of PD. The biological evaluation method established around PTGS2 can accurately evaluate the quality of Safflower in the treatment of PD, which also proves that the target discrimination theory proposed in this study is scientific.

Indexed as

biopotencymetabolomicsnetwork pharmacologyquality evaluationsafflowertarget-combined quality evaluation

Identifiers

PMID40303929
PMCPMC12037613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.